PepGen stock soars over 100% on positive Phase 2 trial data for DM1 drug
In short
PepGen's stock price surged by more than 100% following the release of positive Phase 2 clinical trial results. The reported data pertains to the biotechnology company's experimental drug developed for the treatment of DM1.
Key points
- PepGen's stock price surged by more than 100% following the release of positive Phase 2 c…: PepGen's stock price surged by more than 100% following the release of positive Phase 2 clinical trial results.
- The reported data pertains to the biotechnology company's experimental drug developed for…: The reported data pertains to the biotechnology company's experimental drug developed for the treatment of DM1.